Permeation Enhancer

A permeation enhancer is an excipient whose job is architectural rather than therapeutic: it transiently lowers the resistance of an epithelial barrier so a co-formulated drug crosses in usable quantity. Transcellular enhancers such as salcaprozate sodium, or SNAC, buffer the local environment and interact with the membrane so the drug partitions through the cell. Paracellular enhancers such as the medium-chain fatty acid salt sodium caprate loosen tight junctions so molecules pass between cells. Both effects are designed to reverse quickly.

The clearest example is oral semaglutide, where SNAC is present in large excess relative to the peptide and creates a brief, localised absorption window in the stomach; bioavailability still lands near one percent and remains sensitive to gastric contents. Oral octreotide uses a caprate-based system on the intestinal tight junctions instead. Enhancers are equally central to intranasal formulations, where alkyl saccharides and similar chemistries raise mucosal permeability.

Enhancement is deliberately non-specific, and that is the safety question. A barrier opened for a peptide is briefly open to bacterial products, food antigens and any co-administered drug, which is why regulators scrutinise chronic tight-junction opening and why enhancer-based products carry administration conditions that separate them from other intake.

The frequent misstatement is that an enhancer protects the peptide from acid or proteases; it does not, and any protection is incidental to the local environment it creates. The other error appears in supplement marketing, where words like liposomal or nano are attached to an oral or topical peptide with no enhancer chemistry, no permeability data and no pharmacokinetics behind them.